Getinge AB
| Date: | 12 Dec 2014 |
|---|---|
| Country: | Sweden |
| Customer: | Getinge AB |
| Amount in EUR: | EUR 70 million |
| Maturity: | 8 years |
| Business sector: | Industry & Real Estate |
Project
The loan has been provided for Getinge’s research and development activities in 2014–2017. The R&D investment programme focuses on advancing new products in the company’s three business areas: medical systems, infection control and extended care.
The R&D activities will take place in Sweden and Denmark.
The Swedish Getinge Group operates in the areas of surgery, intensive care, infection control, care ergonomics and wound care. The company has approximately 15,000 employees in 40 countries.
Fulfilment of NIB's mandate
Competitiveness:
R&D is a main driver of productivity growth and the impact of R&D on productivity is widely distributed, because innovations can be imitated by other companies in the region and sector. The likelihood of skills transfer between Getinge and other companies is quite high, as the medical technology cluster is relatively strong in the member area. In recent years, Getinge has utilised the member area’s ICT competence in developing e.g. clinical applications and control systems. The company’s new location in Lindholmen Science Park, Gothenburg, is expected to yield more collaboration opportunities with other companies and research institutes.
Environment:
The environmental impact potential is assessed as “Neutral”.
Sustainability summary
There is no significant potential for negative environmental impact connected to the implementation of the project.
